Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V6JF
|
|||
| Former ID |
DIB006877
|
|||
| Drug Name |
SAR-104772
|
|||
| Synonyms |
TAFIa inhibitor (stroke), sanofi-aventis; SAR-104772 (oral, stroke), sanofi-aventis
Click to Show/Hide
|
|||
| Indication | Cerebrovascular ischaemia [ICD-11: 8B1Z; ICD-10: I67.8; ICD-9: 434.91] | Phase 1 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carboxypeptidase B2 (CPB2) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pancreatic secretion | ||||
| Protein digestion and absorption | ||||
| Panther Pathway | Plasminogen activating cascade | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028193) | |||
| REF 2 | Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.